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ABSTRACT 
We conducted the first-in-human study of 
18
F-fluoroethyl triazole [Tyr
3
] octreotate (
18
F-
FET-βAG-TOCA) in patients with neuroendocrine tumors (NETs) to evaluate 
biodistribution, dosimetry, and safety. Despite advances in clinical imaging, detection 
and quantification of NET activity remains a challenge, with no universally accepted 
imaging standard. Methods Nine patients were enrolled. Eight patients had sporadic 
NET and one had multiple endocrine neoplasia type 1 (MEN1) syndrome. Patients 
received 137-163MBq (mean 155.7± 8 MBq) of 
18
F-FET-βAG-TOCA. Safety data were 
obtained during and 24 h after radioligand administration. Patients underwent detailed 
whole body PET-CT multi-bed scanning over 4 h with sampling of venous bloods for 
radioactivity and radioactive metabolite quantification. Regions of interest were defined 
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to derive individual and mean organ residence times; effective dose (ED) was 
calculated with OLINDA 1.1. Results All patients tolerated 
18
F-FET-βAG-TOCA with no 
adverse events. Over 60% parent radioligand was present in plasma at 60 min. High 
tumor (primary and metastases)-to-background contrast images were observed.  
Physiological distribution was seen in pituitary, salivary, thyroid and spleen, with low 
background distribution in liver, an organ where metastases commonly occur. The 
organs receiving highest absorbed dose were gallbladder, spleen, stomach, liver, 
kidneys and bladder.  The calculated ED over all subjects (mean ± SD) was 0.029 ± 
0.004 mSv/MBq. Conclusion The favorable safety, imaging and dosimetric profile 
makes 
18
F-FET-βAG-TOCA a promising candidate radioligand for staging and 
management of NETs. Clinical studies in an expanded cohort are ongoing to clinically 
qualify this agent.  
 
Key words: Neuroendocrine, 
18
F-fluroethyl [Tyr
3
] octreotate analog, PET/CT imaging 
 
INTRODUCTION 
Neuroendocrine tumors (NETs) are a heterogeneous group. Once thought of as rare 
tumors, the incidence and prevalence has risen over the last three decades, with 
figures from the National Cancer Institute’s Surveillance, Epidemiology and End 
Results Database showing a 520% increase, now surpassing other gastrointestinal 
tumors and sharing the same incidence rates as tumors of the cervix, and multiple 
myeloma (1). Gastroenteropancreatic-NETs are the most common subtype with small 
bowel being the most frequent site (1, 2). 
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     Clinical presentation can vary and depends on the location of the tumor, presence 
of secretory products, and metastatic potential. Imaging is a pivotal part of clinical 
workup when staging NET patients, as well as to aid in treatment decisions and predict 
response to therapy. Current anatomical imaging modalities, namely ultrasound, 
computed tomography, magnetic resonance imaging and somatostatin receptor 
scintingraphy (SRS), fall short with low sensitivity (82-93%, 73-83%, 89-93%, and 89%, 
respectively) and operator dependence (ultrasound), thereby, greatly underestimating 
the stage of disease (3, 4).  
     Current anatomical imaging modalities, namely ultrasound, computed tomography, 
magnetic resonance imaging and somatostatin receptor scintingraphy (SRS), fall short 
with low sensitivity (82-93%, 73-83%, 89-93%, and 89%, respectively) and operator 
dependence (ultrasound), thereby, greatly underestimating the stage of disease (3,4). 
68
Ga-DOTA-radiolabeled somatostatin analogs (
68
Ga-labeled DOTATOC, DOTANOC, 
or DOTATATE) have been developed for use with PET; more recently 
64
Cu-
DOTATATE has also been developed although the isotope has a branching ratio of 
0.175 and 12.7 h half-life. 
68
Ga-PET is far superior to SRS in terms of resolution and 
sensitivity (5-7). 
     
18
F-somatostatin analogs represent a cyclotron-generated alternative to 
68
Ga 
analogs. Thus, we developed a novel 
18
F-‘click’-labeled octreotate radioligand, 
18
F-
FET-βAG-TOCA, for SSTR-2 receptor imaging (8, 9). 
18
F-FET-βAG-TOCA (Fig.1A), 
synthesized using a versatile two-step method to label [Tyr3] octreotate via copper 
catalyzed azide-alkyne cycloaddition reaction (CuAAC; also known as “click 
chemistry”), was shown to be superior to other 
18
F-octreotate labeled ligands and 
68
Ga-
DOTATATE in pre-clinical models, with good tumor uptake and low non-specific liver 
uptake (8). 
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      We present the first-in-human biodistribution, dosimetry and safety study of this 
radioligand in patients with NETs. 
 
MATERIALS AND METHODS 
Radiopharmaceutical preparation  
18
F-FET-βAG-TOCA was synthesized via the click reaction (9). Briefly, 
18
F-fluoride in a 
solution of oxygen‐18 enriched water was transferred with a sweep of argon gas from 
the cyclotron target to the hotcell containing the automated module for radiochemistry. 
The 
18
F-fluoride was then trapped on an ion exchange cartridge (Sep-Pak QMA-
carbonate Light Cartridge), released into the FASTLab reaction vessel, using 1.5 mL of 
a solution containing Kryptofix® K222 and K2CO3 and evaporated to dryness. A solution 
of 2-azidoethyl-p-toluenesulfonate (6 µL) in dry acetonitrile (1 mL) was added to the 
reaction vessel and the solution was heated to 80°C for 15 min. The formed 
18
F-
fluoroethyl azide was then distilled at 120°C into a vial containing a solution of copper 
sulphate (3.25 mg) in water (25 µL) and a solution of βAG-TOCA (4 mg; obtained 
under contract from ABX (ABX Advanced Biochemical Compounds GmbH, Radeberg, 
Germany) in N,N-dimethylformamide (50 µL). Following distillation, 100 µL of a sodium 
ascorbate solution (56.7 mg in 2 mL of sodium acetate buffer) and 100 µL of a solution 
of bathophenanthroline disulfonic acid disodium salt trihydrate (192 mg) in 2 mL of 
water were added. The resulting mixture was mixed and allowed to react at room 
temperature for five min. The solution was then diluted with water and loaded onto 
semi-prep HPLC for purification. The semi-prep HPLC column (Phenomenex Jupiter 
Proteo, 250 x 10 mm, 4 micron, 90 Å) was eluted at a 3 mL/min flow with a pre-mixed 
solution consisting of water/acetonitrile/ethanol/conc.HCl 740/250/10/1. The product 
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fraction eluting at the retention time corresponding to 
18
F-FET-βAG-TOCA was 
collected, diluted with 30 mL of ascorbic acid solution and passed through a tC18 light 
Sep-Pak cartridge (Waters Corp.). Following an initial SepPak cartridge wash with 
sterile water, 
18
F-FET-βAG-TOCA was eluted off the cartridge with ethanol, 0.9% 
saline for injection and water for injection to produce 
18
F-FET-βAG-TOCA formulated in 
8 mL of maximum 12 % (v/v) ethanol in 0.1 % saline for injection. In the final step, the 
resulting formulation solution was filtered through a 0.2µm sterile filter (Millex GV, 
Sterile, 0.22 µm, Millipore) into its final sterile container. The identity and purity 
(chemical and radiochemical purity) of the final product were determined by HPLC. 
Other quality control tests were performed according to European Pharmacopoeia 
guidelines. 
 
Patients  
This was a prospective first-in-human study in nine patients. All patients included were 
≥.18 yr, with locally advanced or metastatic disease and life expectancy ≥3 mo. Only 
patients who had a positive 
68
Ga-DOTATATE scan within the preceding 6 months were 
enrolled. Patients who had received chemotherapy within 3 weeks or radiotherapy 
within 4 weeks, and those with serious underlying medical illness, or unable to tolerate 
scanning were excluded. Previous imaging was recorded to ascertain disease sites 
alongside histopathology, gut hormones, chromogranin levels (CgA and CgB) and Ki-
67 index. Date and dose of last octreotide/lanreotide injection was recorded where 
relevant. The Leeds East and Humberside Research Ethics Committee approved this 
study and all subjects signed written informed consent. The study was conducted 
according to the Declaration of Helsinki. The administration of radioactivity was 
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approved by the Administration of Radioactive Substances Advisory Committee, U.K. 
The Medicines and Healthcare products Regulatory Agency (UK) gave permission to 
administer the Investigational Medicinal Product (European Clinical Trials number 
2013-003152-20). 
 
Safety 
Safety data was obtained during and 24 h after radioligand administration. Data 
recorded included vital signs (heart rate, blood pressure, respiratory rate, and body 
temperature); physical examination; cardiovascular, lung, abdomen, and neurologic 
examinations; electrocardiogram; and laboratory parameters (serum biochemistry, 
hematology, coagulation, and urinalysis). Any adverse events were recorded using the 
common toxicity criteria (version 4.03: 
http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010_0614_QuickReference_5x7.p
df).  
 
Image Acquisition 
Images were acquired on a Siemens Biograph 6 TruePoint PET/CT scanner (with 
TrueV; extended field of view) with 21.6-cm axial and 60.5-cm transaxial fields of view. 
An attenuation CT scan of each patient was obtained prior to administration of 
18
F-
FET-βAG-TOCA, from the vertex to mid-thigh (CT settings: tube potential, 130 kV; 
exposure, 15 effective mAs; pitch, 1.5; slice thickness, 5 mm; rotation time, 0.6 s; 
resulting in an effective dose of 2.5 mSv. This was then followed by multi-bed whole 
body PET scanning protocol on six occasions within a four-hour period. A break after 
the 4
th
 emission scan allowed voiding to enhance radioligand clearance and was 
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followed by a second CT and the last two multi-bed whole body PET scans 
(Supplemental Table.1). 
     All emission scans were reconstructed using the ordered-subsets expectation 
maximization algorithm (3 iterations and 21 subsets) with corrections for dead time, 
scatter, attenuation and radioactive decay. Volumes of interest (VOIs) for as many of 
the possible ICRP 103 source organs were outlined, using the ANALYZE software 
package (version 11; Biomedical Imaging Resource, Mayo Clinic). All source organs 
were manually outlined on screen using a circular paint-brush of fixed diameter and 
width, by a single investigator to avoid any inter-observer variation.  
 
Blood activity measurements 
Discrete venous bloods and plasma (at 5, 10, 15, 30, 60, 90 and 150 min post 
injection) were obtained for radioactivity counting and metabolite analysis, as 
previously described (8).  
 
Data analysis, Biodistribution and Dosimetry  
The mean non–decay corrected 
18
F activity was obtained for the source organ ROIs at 
each whole body scan time, resulting in time-activity curves. The curves were decay 
corrected to the mid-point of each whole-body scan to most closely represent the 
average activity distribution for the scan. To account for the activity remaining in the 
body at the end of the scan protocol, the time-activity curves were extrapolated from 
the last whole-body scan with the simplification that radioactive decay would be the 
only significant change. The curves were converted to activity per organ using the 
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volume of organs in ICRP 23 reference man (10) and normalized by the injected 
activity to give the fractional uptake in each organ as a function of time. These time-
activity curves were trapezoidally-integrated to generate organ residence times (τ); the 
total number of disintegrations in each source organ per unit injected activity. 
     Bladder radioactivity unlike other organs was calculated taking into account the 
bladder volume changes over the time course of the scan (11-14). The ED was 
calculated using firstly the mean residence time over all subjects for each organ and 
secondly using residence times for individual subjects with OLINDA/EXM v1.1 , which 
uses the organ weighting factors from ICRP 60 (15). 
 
RESULTS  
Patients  
In this prospective study nine patients (6 female and 3 male subjects) were recruited. 
Six patients with gastroenteropancreatic NETs and three with lung NETs. One patient 
had known MEN1 syndrome whilst the other tumors were sporadic. MEN1, an 
autosomal dominant hereditary syndrome where patients develop pituitary, 
parathyroid, pancreatic and adrenal tumors, is detected through familial screening. 
68
Ga-DOTA peptides allow detection of NET lesions in MEN1 syndrome patients and 
can be used as an additional tool to CT. The mean age and weight ± SD were 56 yr ± 
12.8 (range 35-73 yr) and 75.2kg ± 11.8 (66.3-91.2kg), respectively. Study schedule 
(Fig.1B), patient demographics and clinical characteristics (Table.1) are summarized. 
Median (range) CgA and CgB levels reflecting in part the burden of disease (16), were 
95 pmol/l (24-1,567) and 170 pmol/l (58-1,328), respectively.  Tumor staging and 
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grading were in accordance with ENETS consensus classification systems (17).  In our 
cohort of patients 22% [2/9] were graded as G1 (≤2) and 78% [7/9] were G2. 
 
Safety  
There were no adverse or clinically detectable pharmacologic events during the study 
or within 24 h after 
18
F-FET-βAG-TOCA injection. No significant changes in vital signs 
or the results of laboratory studies or electrocardiograms were observed.  
 
Radiopharmaceutical 
18
F-FET-βAG-TOCA formulated for injection was obtained from fluoride in 6.2 ± 2.9 % 
non-decay corrected radiochemical yield (range, 2.0-12.1 %) within 100 min. 
Radiochemical purity was 100 % and specific radioactivity was 374 ± 124 GBq/mol 
(range, 224-562 GBq/mol). The mean ± standard deviation (SD) of the administered 
mass of 
18
F-FET-βAG-TOCA was 0.86 ± 0.26 µg (range, 0.52-1.32 µg). The mean 
administered activity was 155.7± 8 MBq (range, 137-163 MBq). 
 
Metabolite analysis  
The metabolism of 
18
F-FET-βAG-TOCA was analyzed using radio-HPLC (1200 series 
system; Agilent). Typical HPLC chromatograms for subject 1 are illustrated in Fig. 2, A-
D. Over 60% of parent radioligand was detectable in plasma at 60 min and over 30% 
of parent radioligand was detectable at 2.5 h (Supplemental Fig.1). There was rapid 
equilibration of radioactivity in blood with blood/plasma ratio of ~1.5. From the parent 
plasma data, the elimination half-lives of the distribution and terminal/elimination phase 
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were calculated as 2.95 ± 0.87 min and 15.87 ± 6.84 min, respectively (fit: R
2
 range 
0.98-1.0) demonstrating rapid radioligand clearance from the blood compartment. The 
identity of the metabolites are presently unknown; no bone uptake was seen thus 
precluding significant defluorination. 
 
Image Quality  
Images obtained with 
18
F-FET-βAG-TOCA PET/CT showed excellent contrast (Fig. 3). 
The image of patient 1, diagnosed with a small bowel NET and widespread 
metastases (bone, liver) shows avid uptake of 
18
F-FET-βAG-TOCA. Fig.4, shows 
images of a patient with known MEN 1 syndrome and with lesions localized within the 
pancreas.  
 
Biodistribution 
18
F-FET-βAG-TOCA derived radioactivity was visually detectable in the vascular 
compartment, liver, spleen, and kidneys, within the first 6 min of radioligand injection.     
There were no significant differences in organ biodistribution between male and female 
patients (Fig.5). Tissue time activity curves generated for the main source organs are 
shown (Fig.6). Over the next 192 min, increased radioligand localization was seen in 
gall bladder, spleen and bladder.  Physiological uptake was also noted in the pituitary, 
salivary glands, and thyroid. The radioligand also showed high tumor uptake (Fig. 6C) 
and tumor/background contrast in all organs including the liver. Three lesions were 
chosen per patient where available, and in patients with multiple metastases, 3 lesions 
were chosen from different sites. In patients with multiple liver lesions only, 3 clearly 
visible lesions were identified and used for measurement of SUV. 
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     The mean residence times (τ) in male and female patients are shown (Table. 2). 
Overall the radioligand was eliminated rapidly from most organs leading to relatively 
short residence times and low/stable organ radioactivity within 60 min of radioligand 
injection. Bladder radioactivity was variable; an example of bladder time-activity curve 
for subject 1 using the 3 parameter fit model is illustrated (Supplemental Fig.2). 
 
Dosimetry  
The calculated ED using mean organ residence times over all 9 subjects was 0.029 
mSv/MBq. When using time-activity curves for individual subjects, the calculated ED 
ranged from 0.022 to 0.032 mSv, giving a standard deviation of 0.004 mSv. The 
estimated mean absorbed dose to all source organs assuming 2-hour bladder voiding 
scenario in individual patients (1-5) or all patients combined is shown (Fig 7, A-E). The 
organs that received the highest dose (mSv/MBq) in descending order were: 
gallbladder wall (0.149 ±0.007), spleen (0.117 ± 0.036), stomach wall (0.076 ± 0.02), 
liver (0.066 ± 0.009), kidneys (0.065 ± 0.011) and urinary bladder (0.051 ± 0.015). 
 
DISCUSSION 
18
F-FET-βAG-TOCA, a SSTR-2 targeting fluorine-18 radioligand has been shown in 
this first in-man study to be safe and well tolerated. GMP compliant, 
18
F-FET-βAG-
TOCA was produced on an automated platform; synthesis time of 
18
F-FET-βAG TOCA, 
using the “click reaction” (9) was shown to be shorter than other 
18
F-octreotate analogs 
and results in reasonable radioligand yields (18). 
18
F-FET-βAG-TOCA had acceptable 
metabolic stability with little or no defluorination. Intact parent radioligand was 
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detectable in plasma by HPLC throughout the study; radioactivity in urine comprised 
up to 90% of parent radioligand at 90 min after injection (data not shown).         
     Future use of this radioligand should be cognizant of physiological localization. Low 
level physiological localization was seen in the pituitary, salivary glands, thyroid and 
spleen, and elimination via the gall bladder increased over time. Rapid distribution to 
the liver was noted but over time there was gradual elimination of radioligand in this 
organ and background activity proved to be less than other previously described 
18
F-
octreotate based radioligands (18, 19). This is in keeping with pre-clinical studies in 
mice. 
18
F-FET-βAG-TOCA was selected from a library of compounds mainly due to its 
low liver uptake - a common site for metastases in neuroendocrine tumors - while 
retaining reasonably high binding affinity comparable (
18
F-AIF-NOTA-OC) or higher 
than existing clinically applicable radioligands (
68
Ga-DOTATATE) (8, 9).  
     The main pharmacokinetic difference between 
18
F-FET-βAG-TOCA and 
68
Ga-
emitting somatostatin radioligands relates to the highest absorbed dose received by 
source organs, where in descending order the spleen, bladder, kidneys and liver 
receive the highest dose with the latter.
 
 In comparison, for 
18
F-FET-βAG-TOCA, the 
gallbladder received the highest absorbed dose. This is to be expected as 
18
F-FET-
βAG-TOCA had both renal and biliary elimination, while 
68
Ga-based ligands have 
predominantly renal elimination (20-22). In our cohort of patients with liver metastases 
the tumor-to-background ratio for 
18
F-FET-βAG-TOCA in liver (4.23 ± 2.69) was 
broadly similar to that reported for 
68
Ga-DOTANOC (3.4 ± 2.3), 
68
Ga-DOTATOC (2.8 ± 
1.6) and 
68
Ga-DOTATATE (2.0, interquartile range 1.4-2.7) (23-25). 
     The dosimetry of 
18
F-FET-βAG-TOCA was similar to other 
18
F-based radioligands. 
The mean ED was found to be 0.029 ± 0.004 mSv/MBq which is comparable to the ED 
of 
18
F-FDG (0.019 mSv/MBq) (26). Radiation safety of 
18
F-FET-βAG-TOCA was 
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inferred from the organ absorbed dose estimates obtained from our study; all values 
were within the limits suggested by the US Food and Drug Administration Code of 
Federal regulation Title 21, Part 361.1. 
      Although a small cohort of patients, we observed no trend between SUV values 
and blood biomarkers or grade of tumors. Patient 1, for instance, was found to have a 
high tumor burden reflected by high chromogranin CgA and CgB levels and high SUV 
of lesions within liver, bone and bowel, however, patient 3 (lung NET), showed low 
tumor burden with low SUV, but CgA and CgB levels were high. Additionally, patient 7 
(pancreatic NET) was found to have very low levels of CgA despite having widespread 
liver metastases on 
18
F-FET-βAG-TOCA PET/CT. This lack of correlation between 
imaging and biomarkers has also been highlighted in other studies (27, 28) and 
suggest that additional multianalyte biomarkers such as circulating NET gene 
transcripts should be considered in the future (29).       
     The MEN1 syndrome positive patient in our study had previous pituitary surgery 
and therefore showed no uptake within this region (physiological or pathological).  
Imaging with 
18
F-FET-βAG-TOCA detected multiple NETs within the pancreas, and as 
expected there were no differences in SUV values of lesions between the MEN1 
positive patient and other patients with gastroenteropancreatic-NETs or lung NETs.  
     
18
F-FET-βAG-TOCA, has shown initial promise with its ease of synthesis, high 
production yield, and accessibility for large multicenter studies, and clinical studies in 
an expanded cohort, with a single static whole-body imaging protocol based on this 
study, are currently ongoing to clinically qualify the ligand in patients with NET, by 
direct comparison with 
68
Ga-DOTATATE PET/CT. The potential of this somatostatin-
receptor specific radioligand, with high specificity for SSTR type 2, highlights the 
possibility for use both in diagnosis and treatment planning, an attractive option in NET 
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patients. This concept of “Theranostics” (therapies that combine diagnostic and 
therapeutic capabilities into a single agent) in nuclear medicine has gained popularity 
and is one step forward in achieving a “personalized medicine” approach in NET 
patients. While this concept applies directly to 
68
Ga-DOTA radioligands (30) it is 
envisaged that the 
18
F-variant can be used, indirectly, to personalize similar therapies. 
 
CONCLUSION 
We report a novel ‘click’ 
18
F-radiolabeled octreotate PET imaging radiopharmaceutical 
with appropriate safety, dosimetry and distribution properties, which highlights tumor 
lesions with high contrast. With the range of treatment modalities available in the 
management of NETs, the use of an optimal imaging modality, together with blood 
biomarkers in the clinic, is of great importance in the therapeutic decision making 
process of NET patients.   
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TABLE 1 
Patient clinical and pathological characteristics 
 
Patient 
no.  
Primary 
site  
Age 
(yr) 
Sex Grade  Metastatic Ki67 (%) 
(primary 
tumor 
histology) 
Biomarker(pmol/l) 
CgA             CgB 
Previous Treatment 
1 Small 
Bowel 
53 F 2 Liver, Bone >10 1,567 170 Surgery/ RFA/
177
Lu†/ 
Octreotide 
2 Small Bowel 73 F 1 Para-aortic lymph 
nodes, Left SCF‡ 
<1 962 558 Surgery 
3 Lung  56 F 2 Bone <5 507 1,328 Octreotide 
4 Small Bowel 60 F 1 Liver <2 143 73 Surgery/ RFA /
177
Lu 
5 Lung 68 F 2 Mediastinal lymph 
nodes , Bone 
17 47 58 Surgery /RFA/ 
177
Lu 
6 Pancreas  70 M 2 None   5 70 174 Surgery 
7 Pancreas 53 F 2 Liver, Bone   9 95 243 Surgery/ Chemotherapy 
8 Lung 41 M 2 Lung, Liver 12 24 126 Surgery/RFA / 
177
Lu 
9 Pancreas § 35 M 2  None <5 49 124 Surgery 
 
*Radiofrequency ablation  
† 
177
Lutetium –DOTATATE (peptide receptor radionuclide therapy) 
‡ SCF Supraclavicular fossa lymph node 
§ MEN 1 (multiple endocrine neoplasia type 1) 
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 (MBq.h/MBq) 
MALE                                 FEMALE 
Organ                                  Mean                SD               Mean               SD 
Adrenals  0.002 0.0002 0.003 0.0008 
Brain 0.006 0.001 0.007 0.001 
Breasts   0.004 0.001 
Cortical bone 0.049 0.002 0.040 0.016 
Gallbladder † 0.110  0.072 0.019 
Heart contents 0.029 0.014 0.019 0.005 
Heart wall 0.020 0.010 0.013 0.004 
Kidneys 0.088 0.007 0.089 0.026 
Liver 0.478 0.073 0.089 0.084 
Lungs 0.063 0.009 0.067 0.025 
Lower large intestine 0.012 0.002 0.019 0.011 
Muscle 0.709 0.154 0.600 0.154 
Ovaries ‡   0.0005 0.00004 
Pancreas 0.017 0.006 0.010 0.0035 
Red marrow 0.028 0.004 0.050 0.032 
Small intestine 0.094 0.065 0.121 0.055 
Stomach 0.005 0.029 0.066 0.222 
Spleen 0.122 0.019 0.097 0.026 
Testes 0.001 0.0002   
Thyroid 0.001 0.0003 0.0008 0.0003 
Upper large intestine 0.026 0.004 0.028 0.014 
Urinary bladder § 0.075 0.019 0.101 0.028 
Uterus   0.006 0.001 
Remainder 0.523 0.250 0.628 0.025 
* Adrenal glands could not be visualized in 3 subjects. 
†Gallbladder surgically removed in 5 subjects (1 male subject had 
gallbladder in-situ). 
‡ Ovaries could not be visualized in 1 subject due to post-
menopausal atrophy and 2 subjects had previous hysterectomy and 
bilateral salpingo-oophorectomy. 
§ Urinary bladder  is for 2-h voiding model.  SD, standard deviation. 
 
TABLE 2 
Mean Residence Times () of 
18
F-FET-βAG-TOCA for different 
organs in Male (n=3) and Female (n=6) subjects 
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Figure Legends 
 
 
 
 
FIGURE 1. Chemical structure of 
18
F-FET-βAG-TOCA and study design. (A) 
Schematic diagram of chemical structure of 
18
F-FET-βAG-TOCA ;CuSO4, Copper (II) 
sulphate ; Na-ascorbate, Sodium ascorbate; BPDS, Bathophenanthrolinedisulfonate; 
pH 5 NaOAc H2O , Sodium acetate buffer (pH5), water; DMF dimethyl formamide; 
MeCN (8:3:10). (B) PET/CT study timeline. FBC, full blood count; U&Es, urea and 
electrolytes; SUV, standardized uptake values; AUC area under the curve; TAC, time 
activity curves. 
             
A 
B 
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FIGURE 2. Metabolite analysis of 
18
F-FET-βAG-TOCA in patient 1. Typical HPLC 
chromatogram of 
18
F-FET-βAG-TOCA in plasma at 5, 30, 60 and 90 min time-points 
(A, B, C and D respectively), red arrows indicate parent / unmetabolized 
18
F-FET-βAG-
TOCA. Scaling of B, C and D adjusted to allow for visualization of metabolite peaks I, II 
and III (blue arrow). 
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FIGURE 3. 
18
F-FET-βAG-TOCA PET/CT images and corresponding maximum 
intensity projection images in patient 1 (small bowel NET with widespread metastases 
in liver and bone). (A and B) Sagittal images, and (C and D) axial slices showing 
widespread liver and bone metastases. 
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FIGURE 4. 
18
F-FET-βAG-TOCA PET/CT images and corresponding maximum 
intensity projection images in patient with MEN1 syndrome, with pancreatic NETs. (A 
and B) axial slices showing multiple lesions within the pancreas (red arrows). 
 
 
 
 
A B 
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FIGURE 5. Time course biodistribution of 
18
F-FET-βAG-TOCA in male and female 
patients. Maximum intensity-projection images of 
18
F-FET-βAG-TOCA in (A) a female 
patient with liver metastases and (B) a male patient with lung NET. 
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FIGURE 6.  Mean decay corrected time activity curves for source organs and tumors. 
(A and B) SUV mean for bladder, kidneys, gallbladder, pancreas, spleen and liver. (C) 
SUV mean and max for tumors (maximum of 3 lesions chosen per patient). 
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FIGURE 7. Biodistribution and dosimetry of 
18
F-FET-βAG-TOCA. Multibed whole-body 
PET scanning over 192 min was used to determine the absorbed doses per unit 
administered activity (mGy/MBq) of major organs and tissues for each patient (the first 
5 patients are shown). The organ absorbed doses in all patients is shown with mean 
effective dose ± SD (standard deviation). 
Supplementary Materials 
TABLE.S1. Image acquisition protocol. 
FIGURE.S1. (A) Percentage (%) of total radioactivity in the form of parent radioligand remaining in 
plasma at 5, 60 and 150 min and (B) table of percentage (%) of total radioactivity and metabolite 
quantification. 
FIGURE.S2. Bladder time-activity curve for subject 1 using the 3 parameter fit model. 
 
 
     TABLE S1 
Image Acquisition Protocol  
Scan Acquisitions 
 
       Min /bed position 
 
No. of bed positions 
  
Vertex to mid thigh 
Attenuation CT 1    
1 1 6-7 Vertex to mid thigh 
2 2 6-7 Vertex to mid thigh 
3 5 6-7 Vertex to mid thigh 
4 5 6-7 Vertex to mid thigh 
Gap       
Attenuation CT 2     Vertex to mid thigh 
5 7 6-7 Vertex to mid thigh 
6 7 6-7 Vertex to mid thigh 
 
Each scan was 6-7 bed positions, with the inferior border set to mid-thigh and the superior border set 
at the vertex. The acquisition for each bed position was 1, 2, 5, 5, 7 and 7 min for the six time points 
after radioligand injection. 
 
A 
 
 
B 
 
Time 
(min) 
Percentage (%) Total Radioactivity Percentage (%) of Total Radioactivity 
Individual metabolites  
Parent Radioligand Total 
Metabolite(s) 
I II III 
5 94 5.5 5.5           0         0 
10 92 7.6 7.6 0 0 
15 90 9.7 9.7 0 0 
30 84 15.6 15.6 0 0 
60 68 32 22.5 3.1 6 
90 55 45 35.1 4 6.7 
150 34 66 45 6.1 15 
 
Figure.S1. (A) Percentage (%) of total radioactivity in the form of parent radioligand remaining in 
plasma at 5, 60 and 150 min. (B) Table summarizing proportions of parent radioligand and 
metabolite(s) expressed as percentage (%) of total radioactivity. The unidentified metabolites I, II and 
III respectively eluted at the following retention times (min) 7, 5.33 and 4. 
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FIGURE.S2. Bladder time-activity curves for patient 1 using the 3 parameter fit model. Total 
bladder activity was estimated as previously (14). Graph (A) illustrates the bladder model in patient 1, 
with measured and fitted curves, and resulting modelled bladder net activity using a 2 h void interval. 
Graph (B) shows the modelled bladder net activity compared to the measured data extrapolated for 
decay beyond the last measured point.  
